A Phase 2 interventional study of LDE225 in PTCH1 or SMO Activated Solid and Hematologic Tumors, sponsored by Novartis Pharmaceuticals. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-02.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Basal Cell Nevus Syndrome with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Basal Cell Nevus Syndrome · United States.
Among the 20 studies in Basal Cell Nevus Syndrome with a site in United States, this one is the 15th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2014, is one of 10 in phase 2, and was the 8th registered.
35 studies on the registry are indexed under Basal Cell Nevus Syndrome; 4 are open to participants now.
Browse Basal Cell Nevus Syndrome studies →1 of the 20 studies in Basal Cell Nevus Syndrome with a site in United States is open now. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Basal Cell Nevus Syndrome studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 3
First in 2004; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 24 across 25 interventional studies indexed under Basal Cell Nevus Syndrome.
Median enrollment 35 across the 18 interventional studies, 765 across the 2 observational. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 4 studies filed under Basal Cell Nevus Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Basal Cell Nevus Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule.
Drug: LDE225
LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
Summary of Overall Response (ORR) and Clinical Benefit (CBR)
Clinical benefit rate (CBR) Number and percentage of subjects with CBR (responses of CR, PR or SD ≥ 16 weeks) as assessed by investigator was reported for all patients along with 95% exact confidence interval (CI). Overall Response Rate (ORR) Overall response was to be determined by investigator assessment for each tumor in the study. For subjects with solid tumors, the assessment criteria was RECIST 1.1 and included responses of CR and/or PR. The number and percentage of subjects for different categories of overall response (e.g., for solid tumors - CR, PR, SD, PD, Not Evaluable) were to be provided for solid tumors, and each hematological tumor type (if applicable). Ninety-five percent (95%) exact CI was to be provided for the response rate(s) (e.g., for solid tumors - CRn and/or PR) as well.
Time frame: 16 weeks
Summary of Timing and Estimated Rate for Progression-free Survival (PFS) - Full Analysis Set
Progression-free survival (PFS) is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause within 30 days of last dose. If a subject has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.
Time frame: 4 months
Kaplan-Meier Estimates of Progression Free Survival (PFS )Timing, Months
Time frame: 4 months
The study was closed for accrual when the sponsor realized that not enough patients will be recruited for any meaningful stat analysis even if the study were kept open beyond the original planned accrual window.
| Milestone | Sonidegib |
|---|---|
| Started | 10 |
| Completed | 0 |
| Not completed | 10 |
| Withdrew: Disease progression | 7 |
| Withdrew: Adverse event | 3 |
Clinical benefit rate (CBR) Number and percentage of subjects with CBR (responses of CR, PR or SD ≥ 16 weeks) as assessed by investigator was reported for all patients along with 95% exact confidence interval (CI). Overall Response Rate (ORR) Overall response was to be determined by investigator assessment for each tumor in the study. For subjects with solid tumors, the assessment criteria was RECIST 1.1 and included responses of CR and/or PR. The number and percentage of subjects for different categories of overall response (e.g., for solid tumors - CR, PR, SD, PD, Not Evaluable) were to be provided for solid tumors, and each hematological tumor type (if applicable). Ninety-five percent (95%) exact CI was to be provided for the response rate(s) (e.g., for solid tumors - CRn and/or PR) as well.
| percent responders | Sonidegib |
|---|---|
| Complete response (CR) | 0 |
| Partial response (PR) | 0 |
| Stable disease (SD) | 0 |
| Progressive disease (PD) | 8 |
| Non-evaluable (NE) | 2 |
| Overall response rate (ORR: CR+PR) | 0 |
| Clinical benefit rate (CBR: CR+PR+SD) | 0 |
Progression-free survival (PFS) is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause within 30 days of last dose. If a subject has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.
| % progression free surviors | Sonidegib |
|---|---|
| 1 Month | 88.9 (43.3 to 98.4) |
| 2 Months | 33.3 (7.8 to 62.3) |
| 3 Months | 33.3 (7.8 to 62.3) |
| 4 Months | 0.0 (NA to NA) |
| months | Sonidegib |
|---|---|
| Kaplan-Meier Estimates of Progression Free Survival (PFS )Timing, Months | 1.8 (0.9 to 3.6) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LDE225 | — | 7/10 (70%) | 10/10 (100%) |
| Event | LDE225 |
|---|---|
| Abdominal painGastrointestinal disorders | 2/10 |
| DehydrationMetabolism and nutrition disorders | 2/10 |
| DysphagiaGastrointestinal disorders | 1/10 |
| Small intestinal obstructionGastrointestinal disorders | 1/10 |
| PneumoniaInfections and infestations | 1/10 |
| Failure to thriveMetabolism and nutrition disorders | 1/10 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/10 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/10 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 1/10 |
| Event | LDE225 |
|---|---|
| NauseaGastrointestinal disorders | 8/10 |
| FatigueGeneral disorders | 6/10 |
| Decreased appetiteMetabolism and nutrition disorders | 5/10 |
| VomitingGastrointestinal disorders | 4/10 |
| Weight decreasedInvestigations | 4/10 |
| ConstipationGastrointestinal disorders | 3/10 |
| DiarrhoeaGastrointestinal disorders | 3/10 |
| Urinary tract infectionInfections and infestations | 3/10 |
| Alanine aminotransferase increasedInvestigations | 3/10 |
| Aspartate aminotransferase increasedInvestigations | 3/10 |
| Age, Categorical(Participants) | Sonidegib |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 4 |
| >=65 years | 6 |
| Age, Continuous(years) | Sonidegib |
|---|---|
| Mean | 63.2 ± 7.64 |
| Sex: Female, Male(Participants) | Sonidegib |
|---|---|
| Female | 6 |
| Male | 4 |
The record gives a start of Feb 2014, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonidegib